Stempoint Capital
JSPR icon

Stempoint Capital’s Jasper Therapeutics JSPR Stock Holding History

Stempoint Capital’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,508
Closed -$2.89M – 71
2024
Q4 		$2.89M Buy
+4,508
New +$2.82M 0.72% 38
2024
Q3 		– Sell
-4,793
Closed -$3.26M – 62
2024
Q2 		$3.26M Buy
4,793
+486
+11% +$350K 0.96% 33
2024
Q1 		$3.79M Buy
+4,307
New +$2.3M 1% 30

Other funds holding JSPR

Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Velan Capital Investment Management
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return
Qiming U.S. Ventures Management
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Integral Health Asset Management
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Rock Springs Capital Management
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Stempoint Capital's JSPR Position: Q1 2025 in Review

Stempoint Capital sold out of Jasper Therapeutics (JSPR) in Q1 2025, closing a stake of 4,508 shares — an estimated $2.89M sold.

Stempoint Capital first reported a position in JSPR in Q1 2024 and held it in 3 quarters. The position peaked at $3.79M in Q1 2024. 67 funds tracked by Wall St. Rank hold JSPR as of Q1 2025.

  • Stempoint Capital reported no remaining Jasper Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Stempoint Capital sold 4,508 Jasper Therapeutics shares in Q1 2025, an estimated $2.89M.
  • Stempoint Capital first reported a position in Jasper Therapeutics in Q1 2024 and held it in 3 quarters.
  • Stempoint Capital's Jasper Therapeutics position peaked at $3.79M in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2025.

Based on Stempoint Capital's 13F filing for Q1 2025, filed 15 May 2025.